<DOC>
	<DOCNO>NCT03026478</DOCNO>
	<brief_summary>Oral Lichen Planus ( OLP ) autoimmune , chronic inflammatory mucocutaneous disease characterize pain burning sensation . The major type OLP follow : reticular , atrophic , erosive-ulcerative , bullous pigmentous form.Its etiology remain unclear . The presence auto-cytotoxic T cell clone lesion suggest role autoimmunity . Numerous treatment option OLP include topical systemic agent depend severity lesion . Topical corticosteroid abide mainstay therapy , widely accept primary treatment choice.Hence study design evaluate compare clinical efficacy topical Clobetasol 0.05 % orabase Betamethasone 0.05 % orabase combination Clotrimazole 1 % management symptomatic Oral Lichen Planus .</brief_summary>
	<brief_title>Topical Betamethasone Clobetasol Orabase Oral Lichen Planus</brief_title>
	<detailed_description>Patients either sex , irrespective age attend Department Oral Medicine &amp; Radiology , Panineeya Mahavidhyalaya Institute Dental Sciences Research Centre , Hyderabad clinically histopathologically diagnosed Oral Lichen Planus shall include study group obtain informed consent patient . Study design : Prospective study . Sample size : A total 30 patient randomly divide 2 group 15 patient group . Methodology : 30 patient diagnosed Oral Lichen Planus clinical histopathological examination randomly assign 2 drug group burn sensation assess VAS Scale also clinical improvement assess interval 1 week till 4 week . GROUP A : This group patient receive topical Clobetasol 0.05 % orabase Clotrimazole 1 % . GROUP B : This group patient receive topical Betamethasone 0.05 % orabase Clotrimazole 1 % . Inclusion criterion : 1 . Patients Oral Lichen Planus , willing participate study . 2 . Patients physically healthy well oriented time , space person . 3 . Patients clinically histopathologically diagnosed Oral Lichen Planus . 4 . Patients symptoms i.e . pain burn sensation due oral lichen planus . Exclusion Criteria : 1 . Patients Oral Lichen Planus , willing participate study . 2 . Patients mucosal disease skin disease may associate oral lesion . 3 . Patients know allergy contraindication study medication . 4 . Patients known history systemic disease , steroid contraindicate . 5 . Pregnant woman .</detailed_description>
	<mesh_term>Lichen Planus , Oral</mesh_term>
	<mesh_term>Lichen Planus</mesh_term>
	<mesh_term>Betamethasone benzoate</mesh_term>
	<mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
	<mesh_term>Betamethasone</mesh_term>
	<mesh_term>Betamethasone Valerate</mesh_term>
	<mesh_term>Clobetasol</mesh_term>
	<mesh_term>Betamethasone sodium phosphate</mesh_term>
	<mesh_term>Benzocaine</mesh_term>
	<criteria>1 . Patients Oral Lichen Planus , willing participate study . 2 . Patients physically healthy well oriented time , space person . 3 . Patients clinically histopathologically diagnosed Oral Lichen Planus . 4 . Patients symptoms i.e . pain burn sensation due oral lichen planus . 1 . Patients Oral Lichen Planus , willing participate study . 2 . Patients mucosal disease skin disease may associate oral lesion . 3 . Patients know allergy contraindication study medication . 4 . Patients known history systemic disease , steroid contraindicate . 5 . Pregnant woman .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>oral lichen planus</keyword>
	<keyword>betamethasone</keyword>
	<keyword>clobetasol</keyword>
	<keyword>orabase</keyword>
</DOC>